VivoSim Labs, Inc. (VIVS)

VivoSim Labs, Inc. is a San Diego-based biotechnology company. It was formerly known as Organovo Holdings, a pioneer in 3D bioprinting of human tissues. The company changed its name and refocused its strategy after selling its lead drug program for inflammatory bowel disease.

VivoSim builds three-dimensional human tissue models, including liver and intestinal models. Pharmaceutical and biotech companies use these models to test drug candidates for toxicity and other effects before clinical trials. The company presents its human-cell-based models as a way to predict human responses better than traditional animal testing, and it offers them as services to drug developers.

Its common stock trades on the Nasdaq under the ticker VIVS.